Literature DB >> 8050588

Glucagon-like peptide 1: a potent glycogenic hormone.

I Valverde1, M Morales, F Clemente, M I López-Delgado, E Delgado, A Perea, M L Villanueva-Peñacarrillo.   

Abstract

GLP-1(7-36)amide is an insulinotropic peptide derived from the intestinal post-translational proglucagon process, the release of which is increased mainly after a carbohydrate meal; also, its anti-diabetogenic effect in normal and diabetic states has been reported. In this study, GLP-1(7-36)amide stimulates the formation of glycogen from glucose in isolated rat hepatocytes, such a glycogenic effect being achieved with physiological concentrations of the peptide. The GLP-1(7-36)amide-induced glycogenesis is abolished by glucagon, and it is accompanied by stimulation of the glycogen synthase alpha activity and by a decrease in the basal and glucagon-stimulated cyclic AMP content. These findings could explain, at least in part, the GLP-1(7-36)amide insulin-independent plasma glucose lowering effect.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8050588     DOI: 10.1016/0014-5793(94)00699-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  19 in total

1.  Antidiabetogenic action of truncated glucagon-like peptide-1 in mice.

Authors:  B Ahrén
Journal:  Endocrine       Date:  1995-05       Impact factor: 3.633

2.  Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice.

Authors:  Xiaokun Ding; Neeraj K Saxena; Songbai Lin; Nitika Arora Gupta; Narita Gupta; Frank A Anania
Journal:  Hepatology       Date:  2006-01       Impact factor: 17.425

3.  Glucagon-like peptide-1(7-36) amide and glycogen synthesis in the liver.

Authors:  Y Nakagawa; K Kawai; H Suzuki; S Ohashi; K Yamashita
Journal:  Diabetologia       Date:  1996-10       Impact factor: 10.122

4.  Inositolphosphoglycans are possible mediators of the glucagon-like peptide 1 (7-36)amide action in the liver.

Authors:  M A Trapote; F Clemente; C Galera; M Morales; A I Alcántara; M I López-Delgado; M L Villanueva-Peñacarrillo; I Valverde
Journal:  J Endocrinol Invest       Date:  1996-02       Impact factor: 4.256

5.  Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models.

Authors:  M L Villanueva-Peñacarrillo; J Puente; A Redondo; F Clemente; I Valverde
Journal:  Endocrine       Date:  2001-07       Impact factor: 3.633

6.  GLP-1 does not not acutely affect insulin sensitivity in healthy man.

Authors:  L Orskov; J J Holst; J Møller; C Orskov; N Møller; K G Alberti; O Schmitz
Journal:  Diabetologia       Date:  1996-10       Impact factor: 10.122

7.  Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons.

Authors:  D A D'Alessio; R Vogel; R Prigeon; E Laschansky; D Koerker; J Eng; J W Ensinck
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

8.  Failure of GLP-1(7-36)amide to affect glycogenesis in rat skeletal muscle.

Authors:  C Fürnsinn; K Ebner; W Waldhäusl
Journal:  Diabetologia       Date:  1995-07       Impact factor: 10.122

9.  Neonatal exendin-4 treatment reduces oxidative stress and prevents hepatic insulin resistance in intrauterine growth-retarded rats.

Authors:  Elisabeth L Raab; Patricia M Vuguin; Doris A Stoffers; Rebecca A Simmons
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-10-21       Impact factor: 3.619

Review 10.  CNS GLP-1 regulation of peripheral glucose homeostasis.

Authors:  Darleen Sandoval
Journal:  Physiol Behav       Date:  2008-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.